RankingsPricing
  1. US-listed companies
  2. ACADIA PHARMACEUTICALS INC
  3. Financials
  4. Cash from investing

ACADIA PHARMACEUTICALS INCACAD

Market cap
$4B
P/E ratio
SummaryFinancials
Period EndCash from investing (Million USD)YoY (%)
Dec 31, 2024-31-195.44%
Dec 31, 202332-56.31%
Dec 31, 202273-203.01%
Dec 31, 2021-71-136.93%
Dec 31, 2020193-216.08%
Dec 31, 2019-166+131.97%
Dec 31, 2018-71-177.31%
Dec 31, 201792-135.31%
Dec 31, 2016-262-277.49%
Dec 31, 2015148-269.09%
Dec 31, 2014-87-30.79%
Dec 31, 2013-126+393.98%
Dec 31, 2012-26-526.89%
Dec 31, 20116

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)